Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR-NBL2 high-risk neuroblastoma phase 3 study
NL-OMON60862Phase 3Recruiting
- Sponsor
- Gustave Roussy
- Start
- Nov 2024
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of melphalan, busulfan, thiotepa, irinotecan, temozolomide and 1 more in neuroblastoma (5 arms), sponsored by Gustave Roussy. Primary endpoints: 3-year event-free survival for R-HDC, 3-year event-free survival for R-RTx and 1 more. Started Nov 2024; status: recruiting.
02
Drugs
melphalanbusulfanthiotepairinotecantemozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON60862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60862.